Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis
Table 1
Clinical characteristics of patients with hepatocellular carcinoma and PVTT.
Characteristics
Therapeutic responses
value
CR, PR
SD, PD
Age (years), median (range)
60 (36–78)
58 (21–94)
0.681
Male : female
27 : 8
89 : 25
0.908
Hepatitis B virus
0.041
Yes
14 (40.0%)
68 (59.6%)
No
21 (60.0%)
46 (40.4%)
Hepatitis C virus
0.003
Yes
20 (57.1%)
34 (29.8%)
No
15 (42.9%)
80 (70.2%)
Maximum tumor size (cm) Median (range)
5.0 (0.8–14.4)
5.6 (0.5–19.0)
0.951
AFP (ng/mL), median (range)
216.0 (2.0–33327.0)
294.0 (2.4–1183010)
0.062
Tumor number
0.808
Solitary
14 (40.0%)
43 (37.7%)
Multiple
21 (60.0%)
71 (62.3%)
Tumor distribution
0.856
Unilobar
23 (65.7%)
73 (64.0%)
Bilobar
12 (34.3%)
41 (36.0%)
Portal vein tumor thrombosis
0.053
Vp4
10 (28.6%)
46 (40.4%)
Vp3
12 (34.3%)
49 (43.0%)
Vp2
13 (37.1%)
18 (15.8%)
Vp1
0
1 (0.8%)
Duration of radiotherapy (days), median (range)
17 (4–44)
15 (1–52)
0.220
Total radiation dose (Gy), median (range)
39 (20–60)
30 (5–60)
0.097
Radiotherapeutic response of PVTT
<0.0001
CR, PR
21 (60.0%)
14 (12.3%)
SD, PD
14 (40.0%)
67 (58.8%)
N/A
0
33 (28.9%)
Additional locoregional therapy
0.007
Yes
21 (60.0%)
39 (34.2%)
No
14 (40.0%)
75 (65.8%)
Chemotherapy
0.944
Sorafenib
8 (22.8%)
25 (21.9%)
Other
10 (28.6%)
30 (26.3%)
No
17 (48.6%)
59 (51.8%)
CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; AFP: alpha-fetoprotein; PVTT: portal vein tumor thrombosis; Vp1, PVTT in distal portal branches; Vp2, PVTT in second-order portal branches; Vp3, PVTT in first-order portal branches; Vp4, PVTT in the main portal trunk; N/A: not available.
